- Thomas brings 25+ years’ experience in leadership positions across early drug development, commercialisation and life cycle management.
- Previously CEO at Cimeio Therapeutics and former Global Haematology Franchise Head at Roche-Genentech.
- He holds an MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Science in Business Administration from the University of Wisconsin-Stout.
ThomasFuchs
CEO
EdHodgkin
Board Chair
- Ed was previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL), and the former CEO of Resolution Therapeutics.
- Within the Syncona life science team, Ed is involved in creation of new businesses and then fills executive roles within those companies to make them operational.
- Ed was previously CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO).
- Ed holds a degree and DPhil in Chemistry from the University of Oxford, and is a former Chairman of the BIA, the UK’s trade association for innovative life science companies.
LaurenceReid
Non-Executive Director
- Laurence is a highly experienced biotech entrepreneur and leader, currently serving as advisor and board member to companies moving through growth phases, strategic inflections, and other formative stages
- Laurence was previously CEO, President and a Board member at Decibel Therapeutics, leading the company through IPO in 2021 and a 2023 acquisition by Regeneron
- Other roles have included: CEO of Warp Drive Bio (2018 merger with Revolution Medicines), former entrepreneur in residence at Third Rock Ventures (including CEO roles in portfolio companies), and CBO at Alnylam Pharmaceuticals
- Laurence holds a PhD in Biochemistry from the University of London, and BA in Natural Sciences from Cambridge University
MagdaJonikas
NON-EXECUTIVE DIRECTOR
- Magda is a Partner of Syncona Investment Management Ltd.
- Magda was previously an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing.
- Magda holds a PhD in Bioengineering from Stanford University and was a postdoctoral fellow in Harvard Medical School’s Computational Health Informatics Programme.
BarryDavies
CSO
- Barry brings to Mosaic 25 years of drug discovery experience across monotherapy and combination therapies.
- Previously, Barry was senior director, global project leader at Astra Zeneca, in which he led multiple projects from LO to phase 2 proof of concept, mainly in the cell signalling, apoptosis and DNA damage response areas.
- During his 19 years at Astra Zeneca Barry held a number of senior leadership roles, including senior director, clinical and translational scientific alliances, in which he was responsible for partnerships and collaborations in Europe and the Asia-Pacific region. He began his career in the Pharmaceutical industry, as a Team Leader in Cancer Bioscience at AstraZeneca. Subsequently, he progressed to Principal Scientist/Director, leading the preclinical work on multiple drug discovery programmes including the recently approved Capivasertib/Truqap.
- Barry obtained a Bsc (Hons) Class I in Biochemistry and PhD in Cancer metastasis from University of Liverpool. Following postdoctoral work in the laboratory of Prof Bruce Ponder in Cambridge, he established his own research group at the Northern Institute for Cancer Research, University of Newcastle, where he was a group leader, senior lecturer and Cancer Research UK grant holder.
- Barry has a wide global external network and has published over 80 papers in refereed journals (H score of 44).
MathewGarnett
CO-FOUNDER
- Mathew is a Senior Group Leader at the Wellcome Sanger Institute, and has over 20 years’ experience in genomics and cancer therapeutics.
- Mathew is the Sanger Scientific Lead for Open Targets, which aims to use genome-scale experiments and analysis to evaluate new therapeutic targets.
- Mathew performs CRISPR-Cas9 genetic screens in cancer cells to identify new drug targets, which led to the discovery of Werner Syndrome helicase as a synthetic-lethal target in microsatellite unstable cancers. He is also the developer of leading, widely-used cancer therapeutics resources including DepMap and GDSC.
- Mathew completed his PhD in 2005 in the laboratory of Richard Marais at The Institute of Cancer Research (London, UK), where he was involved in the discovery and characterisation of BRAF as a human cancer gene.
EmileVoest
Co-Founder
- Emile is a professor of medical oncology and Senior Group Leader at the Netherlands Cancer Institute and Oncode Institute.
- Emile is a former Chairman of the board of Cancer Core Europe, a collaboration of 7 excellent comprehensive cancer centres.
- Emile is the founder of multiple precision medicine programs, and is a global leader in translational research with an emphasis on genetics, tumour organoids and immunology.
- Until 2021, Emile served as executive medical director of the Netherlands Cancer Institute. He is also an independent, non-executive board member of Sanofi, is co-founder and serves on the non-executive board of the Hartwig Medical Foundation.
